Your browser doesn't support javascript.
loading
A Novel Systemic Inflammation Prognostic Score to Stratify Survival in Elderly Patients With Cancer.
Ruan, Guo-Tian; Xie, Hai-Lun; Deng, Li; Ge, Yi-Zhong; Zhang, Qi; Wang, Zi-Wen; Zhang, Xi; Zhang, He-Yang; Tang, Meng; Song, Meng-Meng; Zhang, Xiao-Wei; Yang, Ming; Pan, Lei; Wang, Kun-Hua; Cong, Ming-Hua; Gong, Yi-Zhen; Wang, Meng-Yan; Shi, Han-Ping.
Afiliación
  • Ruan GT; Department of Gastrointestinal Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Xie HL; Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Deng L; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China.
  • Ge YZ; Department of Gastrointestinal Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Zhang Q; Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Wang ZW; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China.
  • Zhang X; Department of Gastrointestinal Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Zhang HY; Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Tang M; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China.
  • Song MM; Department of Gastrointestinal Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Zhang XW; Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Yang M; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China.
  • Pan L; Department of Gastrointestinal Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Wang KH; Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Cong MH; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China.
  • Gong YZ; Department of Gastrointestinal Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Wang MY; Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Shi HP; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China.
Front Nutr ; 9: 893753, 2022.
Article en En | MEDLINE | ID: mdl-35866083
ABSTRACT

Background:

Elderly patients with cancer face the challenge of systemic inflammation, which can lead to a poor prognosis. Existing inflammatory indices cannot fully reflect the immune-inflammatory status of patients. This study aimed to develop a new scoring system to predict the survival of elderly patients with cancer using inflammatory indices, namely, the systemic inflammation prognostic score (SIPS). Materials and

Methods:

This prospective multicenter study included a total of 1,767 patients with cancer, with a mean age of 70.97 ± 5.49 years, of whom 1,170 (66.2%) were men. We performed the least absolute shrinkage and selection operator (LASSO) regression to screen inflammatory indicators to include in constructing SIPS. Prognostic analysis of SIPS was performed using univariate and multivariate survival analyzes. The prognostic value of SIPS and its components were compared using the prognostic receiver operating characteristic curve and concordance index. The population was divided into the training cohort and the validation cohort in a 73 ratio and a SIPS prognostic analysis was performed.

Results:

The LASSO regression selected C-reactive protein (CRP) (≤ 9.81, "0"; > 9.81, "1"), geriatric nutritional risk index (GNRI) (≤ 93.85, "1"; 93.85, "0"), advanced lung cancer inflammation index (ALI) (≤ 23.49, "1"; > 23.49, "0"), and lymphocyte to C-reactive protein ratio (LCR) (≤ 2523.81, "1"; > 2523.81, "0") to develop SIPS. Patients were divided into the three groups based on the total SIPS low-risk (0), moderate-risk (1-2), and high-risk (3-4). On the multivariate survival analysis, patients in the moderate-risk [P < 0.001, hazard ratio (HR) = 1.79, 95% CI 1.47-2.17] and high-risk groups (P < 0.001, HR = 2.40, 95% CI 1.98-2.92) showed a worse prognosis than those in the low-risk group. The total cohort, training cohort, and validation cohort all showed that SIPS had better survival prediction than CRP, GNRI, ALI, and LCR. The HRs were 2.81 times higher in patients in the high-risk group with malnutrition than in patients in the low-risk group without malnutrition.

Conclusion:

SIPS was an independent prognostic indicator in elderly patients with cancer. Malnutrition in the high-risk group increased the mortality risk.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Front Nutr Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Front Nutr Año: 2022 Tipo del documento: Article País de afiliación: China